PALO ALTO, Calif., Oct. 10, 2014 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (Nasdaq:CBMG) (the "Company"), a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, today announced that Professor Zhong Chen Kou, Chief Scientist of Immunology for the Company, will present "Assay for Monitoring T Cell Clonality Response to Cancer Immunotherapy" at the 2014 China Biotherapy Conference on October 12, at 9:55 a.m. Beijing time at the Beijing National Convention Center.
This annual conference takes place on October 11 and 12, 2014 and is jointly sponsored by Cellular Biomedicine Group, Chinese Medical Doctor Association, Hospital 301, Armed Police General Hospital and Chinese Biomedical Engineering Institute of Technology. Medical experts, scholars and entrepreneurs from China and abroad will meet to discuss cancer biotherapy, tissue and organ repair, regenerative medicine, laboratory management, and industry policy developments.
"Our sponsorship of this annual conference supports our commitment to broadening the knowledge within the health care industry and positions us at the forefront of new technologies in cell therapy amongst key influencers," commented Dr. William (Wei) Cao, Chief Executive Officer of Cellular Biomedicine Group.
About Cellular Biomedicine Group
Cellular Biomedicine Group, Inc. develops proprietary cell therapies for the treatment of certain degenerative diseases and cancers. Our developmental stem cell, progenitor cell, and immune cell projects are the result of research and development by scientists and doctors from China and the United States. Our flagship GMP facility, consisting of eight independent cell production lines, is designed, certified and managed according to U.S. standards. To learn more about CBMG, please visit: www.cellbiomedgroup.com.
Statements in this press release relating to plans, strategies, trends, specific activities or investments, and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include, but are not limited to, risk factors inherent in doing business. Forward-looking statements may be identified by terms such as "may," "will," "expects," "plans," "intends," "estimates," "potential," or "continue," or similar terms or the negative of these terms. Although CBMG believes the expectations reflected in the forward-looking statements are reasonable, they cannot guarantee that future results, levels of activity, performance or achievements will be obtained. CBMG does not have any obligation to update these forward-looking statements other than as required by law.
CONTACT: Sarah Kelly Director of Corporate Communications, CBMG +1 650 566-5064 email@example.com Vivian Chen Managing Director Investor Relations, Grayling +1 646 284-9427 firstname.lastname@example.org
Source:Cellular Biomedicine Group Inc.